Respiratory syncytial virus: promising progress against a leading cause of pneumonia

Lancet Glob Health. 2021 Dec;9(12):e1644-e1645. doi: 10.1016/S2214-109X(21)00455-1. Epub 2021 Nov 11.
No abstract available

MeSH terms

  • Antiviral Agents / therapeutic use
  • Humans
  • Pneumonia / prevention & control*
  • Respiratory Syncytial Virus Infections / prevention & control*
  • Respiratory Syncytial Virus Vaccines / immunology
  • Respiratory Syncytial Virus, Human*

Substances

  • Antiviral Agents
  • Respiratory Syncytial Virus Vaccines

Associated data

  • ClinicalTrials.gov/NCT04424316
  • ClinicalTrials.gov/NCT04605159
  • ClinicalTrials.gov/NCT03979313
  • ClinicalTrials.gov/NCT04767373